Canakinumab by O'Horo, John C
Canakinumab
Indications/Dosage
expand all | collapse all
Labeled
Off-Label
† Off-label indication
For the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including
Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome
(MWS)
Subcutaneous dosage
Adults, Adolescents, and Children 4 years and older and weight more than 40
kg
150 mg subcutaneously every 8 weeks.[41378] The efficacy of canakinumab was evident in most patients
during the pivotal clinical trial after only 1 dose; symptoms of Cryopyrin-Associated Periodic Syndromes
(CAPS) diminished within 24 hours in responding patients. The median C-reactive protein (CRP) and
serum amyloid A protein (SAA) concentrations fell to within the normal range. Most (81%) of patients who
stopped receiving canakinumab experienced a disease flare; the median time until the disease flare was
100 days. All patients who continued therapy with canakinumab maintained normal CRP and SAA
concentrations. Upon reinitiation canakinumab, patients who experienced a disease flare responded
again. At the end of the 48-week trial, 30 of 31 patients had no or minimal disease activity, according to
the physician's assessment.[41379]
Adults, Adolescents, and Children 4 years and older and weight 15 to 40 kg
2 mg/kg subcutaneously every 8 weeks. If response is inadequate in children in this weight range, may
consider dose increase to 3 mg/kg subcutaneously every 8 weeks.[41378]
cryopyrin-associated periodic syndromes
(CAPS)
familial mediterranean fever
hyperimmunoglobulin D syndrome
systemic juvenile idiopathic arthritis
tumor necrosis factor receptor associated
periodic syndrome
coronavirus disease 2019 (COVID-19) † severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection †
For the treatment of active systemic juvenile idiopathic arthritis (SJIA)
Subcutaneous dosage
Children and Adolescents 2 years and older and weight 7.5 kg or more
4 mg/kg (Max: 300 mg/dose) subcutaneously every 4 weeks.[41378]
For the treatment of tumor necrosis factor receptor associated periodic syndrome
(TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency
(HIDS/MKD), and familial mediterranean fever (FMF)
Subcutaneous dosage
Adults, Adolescents, and Children 2 years and older and weight more than 40
kg
150 mg subcutaneously every 4 weeks. The dose can be increased to 300 mg subcutaneously every 4
weeks if the clinical response is not adequate. During clinical trials, canakinumab was superior to
placebo in the proportion of patients who resolved their disease flare by Day 15 and had no new flare
over the next 16 weeks of treatment.[41378]
Adults, Adolescents, and Children 2 years and older and weight less than 40 kg
2 mg/kg subcutaneously every 4 weeks. May increase to 4 mg/kg subcutaneously every 4 weeks if the
clinical response is not adequate. During clinical trials, canakinumab was superior to placebo in the
proportion of patients who resolved their disease flare by Day 15 and had no new flare over the next 16
weeks of treatment.[41378]
INVESTIGATIONAL USE: For adjunctive use in the treatment of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the virus that causes
coronavirus disease 2019 (COVID-19)†
Intravenous dosage
Adults
Efficacy has not been established. Due to a lack of clinical data, the National Institutes of Health (NIH)
COVID-19 treatment guidelines do not give recommendations for or against the use of IL-1 antagonists,
such as canakinumab.[65314] Dosing regimens being evaluated include: 4 mg/kg and 8 mg/kg IV once
for patients 40 kg or less; 300 mg and 600 mg IV once for patients more than 40 kg; 450 mg IV once for
patients 40 to 59 kg; 600 mg IV once for patients 60 to 80 kg; 750 mg IV once for patients more than 80
kg. All doses are to be diluted in 250 mL of 5% dextrose and infused over 2 hours.[65390] [65393]
Subcutaneous dosage
Adults
Efficacy has not been established. Due to a lack of clinical data, the National Institutes of Health (NIH)
COVID-19 treatment guidelines do not give recommendations for or against the use of IL-1 antagonists,
such as canakinumab.[65314] A single 150 mg subcutaneous injection is being evaluated in a
retrospective and prospective observational study.[65392]
Maximum Dosage Limits
Adults
CAPS
more than 40 kg: 150 mg/dose subcutaneously every 8 weeks.
40 kg or less: 3 mg/kg/dose subcutaneously every 8 weeks.
TRAPS, HIDS/MKD, FMF
more than 40 kg: 300 mg/dose subcutaneously every 4 weeks.
40 kg or less: 4 mg/kg/dose subcutaneously every 4 weeks.
Geriatric
CAPS
more than 40 kg: 150 mg/dose subcutaneously every 8 weeks.
40 kg or less: 3 mg/kg/dose subcutaneously every 8 weeks.
TRAPS, HIDS/MKD, FMF
more than 40 kg: 300 mg/dose subcutaneously every 4 weeks.
40 kg or less: 4 mg/kg/dose subcutaneously every 4 weeks.
Adolescents
CAPS
more than 40 kg: 150 mg/dose subcutaneously every 8 weeks.
15 to 40 kg: 3 mg/kg/dose subcutaneously every 8 weeks.
TRAPS, HIDS/MKD, FMF
more than 40 kg: 300 mg/dose subcutaneously every 4 weeks.
40 kg or less: 4 mg/kg/dose subcutaneously every 4 weeks.
SJIA
7.5 kg or more: 4 mg/kg/dose (Max: 300 mg/dose) subcutaneously every 4 weeks.
Children
CAPS
4 years and older and more than 40 kg: 150 mg/dose subcutaneously every 8 weeks.
4 years and older and 15 to 40 kg: 3 mg/kg/dose subcutaneously every 8 weeks.
Less than 4 years: Safety and efficacy have not been established.
TRAPS, HIDS/MKD, FMF
2 years and older and more than 40 kg: 300 mg/dose subcutaneously every 4 weeks.
2 years and older and 40 kg or less: 4 mg/kg/dose subcutaneously every 4 weeks.
Less than 2 years: Safety and efficacy have not been established.
SJIA
2 years and older and 7.5 kg or more: 4 mg/kg/dose (Max: 300 mg/dose) subcutaneously every 4
weeks.
Less than 2 years: Safety and efficacy have not been established.
Infants
Safety and efficacy have not been established.
Neonates
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
No formal studies have been conducted in patients with hepatic impairment.[41378]
Patients with Renal Impairment Dosing
No formal studies have been conducted in patients with renal impairment.[41378]
† Off-label indication
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How Supplied
Canakinumab Lyophilisate for solution for injection
ILARIS 180mg (150mg/mL) Powder for Injection (00078-0582) (Novartis Pharmaceuticals Corporation) (off market)
Canakinumab Solution for injection
ILARIS 150mg/mL Solution for Injection (00078-0734) (Novartis Pharmaceuticals Corporation)
Description/Classification
Description
Canakinumab (Ilaris) is a human monoclonal antibody against interleukin (IL)-1 beta approved for the treatment
of 2 forms of cryopyrin-associated periodic syndromes (CAPS), Familial Cold Autoinflammatory Syndrome
(FCAS) and Muckle-Wells Syndrome (MWS), in patients 4 years of age and older. Canakinumab is also
approved for adult and pediatric patients for Tumor Necrosis Factor Receptor Associated Periodic Syndrome
(TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial
Mediterranean Fever (FMF). In addition, canakinumab is approved for active Systemic Juvenile Idiopathic
Arthritis (SJIA) in patients 2 years of age and older. Most patients with FCAS and MWS respond positively to
canakinumab. For example, 34 of 35 patients who received a single 150 mg canakinumab subcutaneous dose
had a complete response, which was defined as a physician global assessment of no or minimal disease activity,
an assessment of no or minimal rash, and a C-reactive protein and serum amyloid A protein concentration less
than 10 mg/L. The patient without a complete response had self-injected the drug and had substantially lower
than expected canakinumab concentrations. Continued remission was achieved by all patients who received
canakinumab every 8 weeks through week 24.[41379]
 
Updates for coronavirus disease 2019 (COVID-19):
Due to a lack of clinical data, the National Institutes of Health (NIH) COVID-19 treatment guidelines do not
give recommendations for or against the use of IL-1 antagonists, such as canakinumab.[65314] Based on
preliminary data from other anti-interleukin medications, studies have begun to evaluate the use of canakinumab
for COVID-19.[65390][65392][65393]
Classifications
Antineoplastic and Immunomodulating Agents
Agents that Suppress the Immune System
Interleukin-1 Beta (IL-1 Beta) Inhibitors
Musculo-Skeletal System
Antiinflammatory Agents and Antirheumatic Agents
Specific Anti-Rheumatic Agents
Anti-Rheumtic Monoclonal Antibodies
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Injectable Administration
Visually inspect parenteral products for particulate matter and discoloration prior to administration
whenever solution and container permit.
Subcutaneous Administration
Health care providers should perform administration of canakinumab.[41378]
 
Reconstitution:
Using aseptic technique, slowly inject 1 mL of preservative-free sterile water for injection with a
syringe and an 18-gauge, 2-inch needle.
Slowly swirl the vial at a 45-degree angle for approximately 1 minute; allow to stand for 5 minutes.
Gently turn the vial upside down and back again 10 times. Do NOT shake. Avoid touching the rubber
stopper with your fingers.
Allow the reconstituted solution to stand for about 15 minutes at room temperature to obtain a clear
solution. Tap the side of the vial to remove any residual liquid from the stopper.
The reconstituted solution has a final concentration of 150 mg/mL.
The reconstituted solution should be essentially free from particulates, and should be clear to
opalescent; do not use if particulate matter is present in the solution. The solution should be colorless
or may have a slight brownish-yellow tint; do not use if the solution has a distinctly brown
discoloration. It is not unusual to have slight foaming of the product upon reconstitution.
Storage: If not used within 60 minutes of reconstitution, the solution should be stored in the
refrigerator at 2 to 8 degrees C (36 to 46 degrees F) and used within 4 hours. Protect from light.
[41378]
 
Subcutaneous injection:
Using a sterile 1-mL syringe and needle, carefully withdraw the required volume depending on the
dose to be administered.
Discard any unused product; the vial is for single-use and does not contain any preservatives.
Subcutaneously inject using a 27-gauge, 0.5-inch needle. Avoid injection into scar tissue as this may
result in insufficient exposure to canakinumab.[41378]
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Adverse Reactions
Diarrhea (20%), nausea (14%), and gastroenteritis (11%) were among the most commonly reported adverse
reactions associated with canakinumab during clinical trials in 35 patients with Cryopyrin-Associated Periodic
Syndromes (CAPS). Gastroenteritis was reported in 3% of canakinumab patients in a Tumor Necrosis Factor
Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase
Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF) trial. Among patients with systemic
juvenile idiopathic arthritis, 7% to 16% of canukinumab recipients had upper abdominal pain as compared with
2.4% to 12% of placebo recipients.[41378]
During clinical trials with canakinumab, mean values decreased for white blood cells and neutrophils. Thus,
canakinumab may cause immunosuppression (including leukopenia and neutropenia) and resultant increased risk
of infection including serious infections or activation of latent infections (e.g., tuberculosis). Of 50 canakinumab
recipients for systemic juvenile idiopathic arthritis (SJIA), 10.4% had a WBC less than or equal to 0.8 times the
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lower limit of normal as compared with 4% of the 50 placebo recipients. In the same study, transient decreases
in absolute neutrophil counts (ANC) to less than 1,000 cells/mm3 were reported in 6% of canakinumab
recipients as compared with 2% of placebo recipients. Further, 1 case of ANC counts less than 500 cells/mm3
was observed in the canakinumab group versus none in the placebo group. Infections, predominately upper
respiratory tract infections, have been reported with the use of canakinumab. Some of these infections were
reported as serious and generally responded to standard therapy. Isolated cases of opportunistic or rare infections
(e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) also have been reported
with canakinumab therapy; a causal relationship with canakinumab cannot be excluded.[41378] An increased
incidence of serious infections has been associated with the administration of IL-1 blockers in combination with
tumor necrosis factor inhibitors. One patient experienced a recurrent antibiotic-resistant lower urinary tract
infection and sepsis (requiring hospital admission and study withdrawal).[41379] In 1 patient who received
canakinumab, an intra-abdominal abscess after appendectomy was reported. However, most infections reported
in clinical trials involved the upper respiratory tract. In a phase 3 clinical trial of 35 patients with Cryopyrin-
Associated Periodic Syndromes (CAPS), adverse events included nasopharyngitis (34%), influenza (17%),
rhinitis (17%), bronchitis (11%), and pharyngitis (11%). Among patients with SJIA, 30.2% to 54.8% of
canakinumab recipients had an infection; the rates were higher in treated patients than in those receiving
placebo. Approximately 4% to 5% of canakinumab patients developed serious infections (e.g., pneumonia,
varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis)
during SJIA clinical trials.[41378] The following infections were reported in the Tumor Necrosis Factor Receptor
Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase
(HIDS/MKD), and Familial Mediterranean Fever (FMF) trial, nasopharynigitis (10.7%), upper respiratory tract
infection (7.1%), rhinitis (5.3%), and pharyngitis (3%). Serious infection (e.g., conjunctivitis, pneumonia,
pharyngitis, pharyngotonsillitis) occurred in 2.4% of canakinumab recipients. Decreases in neutrophil count that
were grade 2 or greater occurred in 6.5% of canakinumab patients in the TRAPS, HIDS/MKD and FMF trial.
Persistent cough could be a symptom of tuberculosis; instruct patients to seek care for a persistent cough, weight
loss, or subfebrile temperature. If a serious infection occurs during treatment, discontinue canakinumab.[41378]
Vertigo was noted in 9% to 14% of canakinumab recipients in studies of Cryopyrin-Associated Periodic
Syndromes (CAPS) and was reported as a serious event in 2 cases. Vertigo occurred exclusively in Muckle-
Wells Syndrome (MWS) patients. Cases of vertigo resolved with continued canakinumab receipt. Headache was
noted in 14% of 35 patients receiving canakinumab for CAPS.[41378]
A subcutaneous injection site reaction to canakinumab was observed in 7% to 9% of patients enrolled in the
Cryopyrin-Associated Periodic Syndromes (CAPS) clinical trials, and all cases were mild or moderate local
tolerability reactions. No severe reactions were reported, and none led to discontinuation of treatment. Among
patients with systemic juvenile idiopathic arthritis (SJIA), 12% or fewer patients had a mild injection site
reaction, and moderate reactions occurred in 2% or less. Injection site reactions may include pain, erythema,
swelling, itching, bruising, mass, inflammation, dermatitis, edema, hives, vesicles, warmth, and local
hemorrhage. Avoid injecting canakinumab into an area that is already swollen or red. In the Tumor Necrosis
Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate
Kinase (HIDS/MKD), and Familial Mediterranean Fever (FMF) trial, mild to moderate injection-site reactions
occurred in 10.1% of canakinumab patients.[41378] [41379]
Weight gain was reported in 11% of 35 patients during clinical trials of canakinumab for the treatment of
Cryopyrin-Associated Periodic Syndromes (CAPS).[41378]
Musculoskeletal pain was reported with the use of canakinumab during clinical trials in 11% of 35 patients with
Cryopyrin-Associated Periodic Syndromes (CAPS).[41378]
Elevated hepatic enzymes have been observed among canakinumab recipients. Transaminases (ALT and/or
AST) greater than 3 times the upper limit of normal (ULN) were noted in 2 (4.1%) of 50 canakinumab recipients
and in 1 of 50 placebo recipients with systemic juvenile idiopathic arthritis (SJIA); all patients had normal
values at the next visit. In addition to elevated hepatic enzymes, hyperbilirubinemia may occur. Asymptomatic
and mild elevations of serum bilirubin have been observed without concomitant elevations of liver
transaminases.[41378]
Hypersensitivity reactions have been reported with canakinumab; anaphylactic reactions were not reported
during clinical trials. Only one patient with Cryopyrin-Associated Periodic Syndromes (CAPS) discontinued a
trial due to hypersensitivity reactions whereas 0% of the patients with systemic juvenile idiopathic arthritis
(SJIA, Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D
Syndrome/Mevalonate Kinase (HIDS/MKD), or Familial Mediterranean Fever (FMF) discontinued trials
because of a hypersensitivity reaction. Instruct patients to get immediate medical help if they develop signs of an
allergic reaction such as difficulty breathing or swallowing, nausea, dizziness, skin rash (unspecified), pruritus,
urticaria, palpitations, or hypotension. Do not readminister the drug if a hypersensitivity reaction occurs:
canakinumab is contraindicated for use by patients with confirmed hypersensitivity to canakinumab or to any of
its excipients. Of note, some symptoms of Cryopyrin-Associated Periodic Syndromes (CAPS) may be similar to
symptoms of hypersensitivity. In patients with CAPS, excessive amounts of interleukin-1 beta may lead to
symptoms such as an urticaria-like skin rash.[41378]
Canakinumab may cause thrombocytopenia. In clinical trials for Cryopyrin-Associated Periodic Syndromes
(CAPS), mean values decreased for platelets. Of 50 canukinumab recipients for systemic juvenile idiopathic
arthritis, 6.3% had transient decreases in platelet counts that were less than the lower limit of normal but greater
than 75,000 cells/mm3 compared to 2% of placebo recipients. In the Tumor Necrosis Factor Receptor Associated
Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase (HIDS/MKD), and
Familial Mediterranean Fever (FMF) trial, 0.6% of canakinumab patients had decreased platelet counts that were
grade 2 or greater.[41378]
Among patients who received canakinumab for Cryopyrin-Associated Periodic Syndromes (CAPS), 1.5% had
antibody formation to the drug, which was detected by a biosensor binding assay. Antibodies to canakinumab
were also detected mostly via a bridging immunoassay among 3.1% of patients with systemic juvenile idiopathic
arthritis who received canakinumab. No neutralizing antibodies were detected, and no apparent correlation of
antibody development to clinical response or adverse events was observed. In the Tumor Necrosis Factor
Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase
(HIDS/MKD), and Familial Mediterranean Fever (FMF) trial, no patients tested positive for anti-canakinumab
antibodies. Several factors strongly affect the data obtained in an assay including assay sensitivity and
specificity, assay methodology, sample handling, timing of sample collection, concomitant medications,
underlying disease, and the number of patients tested. For these reasons, it may be misleading to compare the
incidence of antibodies to canakinumab with the incidence of antibodies to other products.[41378]
Macrophage activation syndrome (MAS) is a life-threatening disorder that may develop in patients with
rheumatic conditions, especially systemic juvenile idiopathic arthritis (SJIA), and it has been reported in SJIA
patients treated with canakinumab in clinical trials. Based on limited data, canakinumab does not appear to
increase the incidence of MAS; 11 cases were observed in 201 patients who received canakinumab for SJIA.
However, infection is a trigger for MAS, and canakinumab is associated with an increased risk of serious
infections. Clinicians should be attentive to symptoms of infection or worsening arthritis symptoms; SJIA
worsening is also a trigger for MAS.[41378] The diagnostic criteria for MAS developed through a collaborative
initiative between the European League Against Rheumatism (EULAR), American College of Rheumatology
(ACR), and Pediatric Rheumatology International Trials Organization are the presence of any two of the
following in a febrile patient with known or suspected SJIA and ferritin greater than 684 ng/mL: platelet count
less than 181,000 cells/mm3, AST greater than 48 units/L, triglycerides greater than 156 mg/dL, and fibrogen
360 mg/dL or less.[65453]
The effect of anti-interleukin-1 (IL-1) therapy with canakinumab on the development of malignancies is not
known. However, treatment with immunosuppressants, including canakinumab, may result in an increase in the
risk of new primary malignancy.[41378]
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Contraindications/Precautions
Absolute contraindications are italicized.
Canakinumab is contraindicated for use in patients with a confirmed hypersensitivity to canakinumab.
Hypersensitivity reactions have been reported with canakinumab therapy. During clinical trials, no anaphylactic
reactions have been reported. It should be recognized that symptoms of the underlying disease being treated may
be similar to symptoms of hypersensitivity.[41378]
Patients who receive canakinumab are at an increased risk of developing serious infections. Canakinumab
should not be initiated in patients with an active infection requiring medical intervention and therapy should be
discontinued if a patient develops a serious infection. Infections, primarily of the upper respiratory tract, in some
instances serious, have been reported with the drug. Generally, the observed infections responded to standard
therapy. Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial
infections, cytomegalovirus, herpes zoster) have been reported with canakinumab therapy. Canakinumab is an
IL-1 blocker that may cause immunosuppression and use is associated with an increased risk of serious
infections. Canakinumab use may also increase the risk of tuberculosis (TB) or other atypical or opportunistic
infections. Prior to initiation of canakinumab, evaluate patients for tuberculosis risk factors and test them for
active or latent tuberculosis. The drug has not been studied in patients with a positive tuberculosis screen.
Patients with positive tuberculosis screening or with known active or latent tuberculosis should be treated before
canakinumab receipt, following the current Centers for Disease Control (CDC) guidelines. Use caution in
patients with infection, including human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C,
history of recurring infections, or underlying conditions that may predispose them to infections.[41378]
The impact of anti-interleukin-1 therapy with canakinumab on the development of neoplastic disease is not
known. However, treatment with immunosuppressants, including canakinumab, may result in an increase in the
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risk of certain malignancies.[41378]
Live vaccines should not be given to patients taking canakinumab; other forms of vaccination should be
completed prior to initiation of therapy. Data are lacking on the efficacy of live vaccines and on the risks of
secondary transmission of infection by live vaccines in patients receiving canakinumab. In addition, limited data
are available on the effectiveness of vaccinations in patients receiving canakinumab; it is possible the drug may
interfere with normal immune response to vaccine antigens. Interleukin-1 blockade may also interfere with
immune response to infections. It is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive all recommended vaccinations (including pneumococcal vaccine and inactivated
influenza vaccine; consult current recommendations of the Centers for Disease Control).[41378] [43236]
Use canakinumab with caution in patients with hepatic disease or renal impairment. No formal studies have been
conducted to examine the pharmacokinetics or use of canakinumab in patients with renal or hepatic impairment.
[41378]
Pregnancy exposure data is insufficient to inform regarding drug-associated risk with canakinumab. Monoclonal
antibodies, such as canakinumab, are transported across the placenta in a linear fashion as pregnancy progresses;
therefore, potential fetal effects are likely to be greater during the second and third trimesters. Canakinumab has
been studied in marmoset monkeys using doses 11-fold the maximum recommended human dose (MRHD) and
greater (based on a plasma area under the time-concentration curve, AUC comparison); delays in fetal skeletal
development were reported. Doses producing exposures within the clinical exposure range at the MRHD were
not evaluated.[41378]
No information is available regarding the presence of canakinumab in breast-milk, the effects on milk
production, or the effects on the breast-fed infant. Excretion of the drug into mature breast milk is considered
unlikely due to the drugs high molecular weight (145,157). Absorption is unlikely because canakinumab is a
protein that will likely be destroyed in the infant's gastrointestinal tract. Because maternal antibodies are known
to be present in colostrum, there is a potential of exposing a nursing infant to the drug during the first few days
after birth. Thus, health care providers are advised to monitor nursing babies for signs of infection as well as
other drug associated adverse effects including nasopharyngitis, diarrhea, rhinitis, nausea, headache, bronchitis,
and gastroenteritis. The FDA-approved product label recommends considering the developmental and health
benefits of breast-feeding, the mother's need for canakinumab therapy, and potential adverse effects of the drug
or an inadequately treated condition on the breast-fed infant.[41378] [61034]
The safety and effectiveness of canakinumab in neonates, infants, and children less than 2 years old have not
been established for Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS),
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), Familial Mediterranean
Fever (FMF), and Systemic Juvenile Idiopathic Arthritis (SJIA). The safety and effectiveness of canakinumab in
neonates, infants, and children less than 4 years old have not been established in Cryopyrin-Associated Periodic
Syndrome (CAPS). Clinical trials with canakinumab included a total of 23 pediatric patients with CAPS, ages 4
years to 17 years (11 adolescents were treated with 150 mg subcutaneously, and 12 children were treated with 2
mg/kg based on body weight 15 kg to 40 kg ). Overall, the efficacy and safety of canakinumab in pediatric and
adult patients were comparable. In the TRAPS, HIDS/MKD, and FMF clinical trial, 102 pediatric patients, ages
2 to 17 years were treated with canakinumab 2 mg/kg subcutaneously every 4 weeks. No clinically meaningful
differences in efficacy, safety, and tolerability were found between adult and pediatric patients.[41378]
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Mechanism of Action
Canakinumab is a human monoclonal antibody against interleukin (IL)-1 beta. Binding of canakinumab to IL-1
beta blocks the interaction with IL-1 receptors. Excessive release of IL-1 beta drives inflammation in patients
with cryopyrin-associated periodic syndromes (CAPS), which is a rare, genetic-based disease. Patients with the
disease have mutations in the NLRP-3 (CIAS1) gene that encodes the protein cryopyrin.[41378] Cryopyrin binds
with an intrinsic inhibitor and controls the activation of caspase-1. Caspase-1 cleaves pro-interleukin-1 beta and
IL-18 into the biologically active forms.[33840] Patients with CAPS have increased caspase activity and thus,
increased biologically active IL-1 beta.
 
Canakinumab has a disease-modifying effect through autocrine down-regulation of IL-1 beta production.[41379]
IL-1 beta has been shown both in vivo and in vitro to stimulate its own production. Unbound IL-1 beta in the
tissue stimulates production of C-reactive protein (CRP) and serum amyloid A protein (SAA), leading to an
increased probability of a disease flare. Canakinumab binds to IL-1 beta and suppresses free IL-1 beta; this
disrupts this feedback mechanism and hence reduces IL-1 production to a rate of that seen in healthy subjects.
[41419]
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Pharmacokinetics
Canakinumab is administered subcutaneously. Canakinumab binds to serum interleukin (IL)-1 beta. The volume
of distribution at steady-state varied with body weight and was estimated to be 6.01 L in a typical patient with
cryopyrin-associated periodic syndromes (CAPS) weighing 70 kg, 3.2 L in a patient weighing 33 kg with
systemic juvenile idiopathic arthritis (SJIA), and 6.34 L for a patient weighing 70 kg with periodic fever
syndrome. Clearance of the drug also varied according to body weight and was estimated to be 0.174 L/day in a
typical 70 kg patient with CAPS, 0.11 L/day in a SJIA patient weighing 33 kg, and 0.17 L/day in a periodic
fever syndrome patient weighing 70 kg. After repeated administration, there was no indication of accelerated
clearance or time-dependent change. The expected accumulation ratio was 1.3-fold for CAPS patients and 1.6-
fold for SJIA patients after 6 months of 150 mg canakinumab subcutaneously every 8 weeks and 4 mg/kg
subcutaneously every 4 weeks, respectively. The mean terminal half-life was 26 days in adults with CAPS
receiving subcutaneous dosing.[41378]
 
Affected cytochrome P450 (CYP450) isoenzymes and drug transporters: various CYP isoenzymes
The formation of CYP450 enzymes is suppressed by increased levels of cytokines (e.g., IL-1) during chronic
inflammation. Thus it is expected that for a molecule that binds to IL-1, such as canakinumab, the formation of
CYP450 enzymes could be normalized. This is clinically relevant for CYP450 substrates with a narrow
therapeutic index (NTI), where the dose is individually adjusted (e.g., warfarin). Upon initiation of
canakinumab, in patients being treated with drugs with an NTI, therapeutic monitoring of the effect or drug
concentration should be performed and the individual dose of the medicinal product may need to be adjusted as
needed.[41378]
Route-Specific Pharmacokinetics
Intravenous Route
Canakinumab has been investigated as an intravenous infusion. Exposure parameters (such as AUC
and Cmax) increased in proportion to dose over the dose range of 0.30 to 10 mg/kg given as
intravenous infusion.[41378]
Subcutaneous Route
The peak serum canakinumab concentration (Cmax) of 16 +/- 3.5 mcg/mL occurred approximately 7
days after subcutaneous administration of a single, 150 mg dose in adult patients with cryopyrin-
associated periodic syndromes (CAPS). The absolute bioavailability of subcutaneous canakinumab
was estimated to be 66%. Exposure parameters (such as AUC and Cmax) increased in proportion to
dose over the dose range of 150 to 300 mg as a subcutaneous injection.[41378]
Special Populations
Hepatic Impairment
No formal studies have been conducted to examine the pharmacokinetics or use of canakinumab in
patients with hepatic impairment.[41378]
Renal Impairment
No formal studies have been conducted to examine the pharmacokinetics or use of canakinumab in
patients with renal impairment.[41378]
Pediatrics
Peak concentrations of canakinumab occurred between 2 to 7 days after single subcutaneous
administration of canakinumab 150 mg or 2 mg/kg in pediatric patients with cryopyrin-associated
periodic syndromes (CAPS). The terminal half-life ranged from 22.9 to 25.7 days, similar to the
pharmacokinetic properties observed in adults. Pharmacokinetic properties of canakinumab are
similar among pediatric patients with CAPS or systemic juvenile idiopathic arthritis (SJIA). Among
patients with SJIA who received 4 mg/kg subcutaneously every 4 weeks, canakinumab exposure
parameters such as AUC and Cmax were comparable across age groups from 2 years of age and
older. Following subcutaneous administration of canakinumab 2 mg/kg every 4 weeks in patients 2
years to less than 20 years of age, trough concentrations were similar among patients with tumor
necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome
(HIDS)/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF).[41378]
Geriatric
No age-related pharmacokinetic differences were observed between geriatric adults and younger
adults after correction for body weight.[41378]
Gender Differences
No pharmacokinetic differences were observed between males and females after correction for body
weight.[41378]
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Pregnancy/Breast-feeding
Pregnancy
Pregnancy exposure data is insufficient to inform regarding drug-associated risk with canakinumab. Monoclonal
antibodies, such as canakinumab, are transported across the placenta in a linear fashion as pregnancy progresses;
therefore, potential fetal effects are likely to be greater during the second and third trimesters. Canakinumab has
been studied in marmoset monkeys using doses 11-fold the maximum recommended human dose (MRHD) and
greater (based on a plasma area under the time-concentration curve, AUC comparison); delays in fetal skeletal
development were reported. Doses producing exposures within the clinical exposure range at the MRHD were
not evaluated.[41378]
Breast-Feeding
No information is available regarding the presence of canakinumab in breast-milk, the effects on milk
production, or the effects on the breast-fed infant. Excretion of the drug into mature breast milk is considered
unlikely due to the drugs high molecular weight (145,157). Absorption is unlikely because canakinumab is a
protein that will likely be destroyed in the infant's gastrointestinal tract. Because maternal antibodies are known
to be present in colostrum, there is a potential of exposing a nursing infant to the drug during the first few days
after birth. Thus, health care providers are advised to monitor nursing babies for signs of infection as well as
other drug associated adverse effects including nasopharyngitis, diarrhea, rhinitis, nausea, headache, bronchitis,
and gastroenteritis. The FDA-approved product label recommends considering the developmental and health
benefits of breast-feeding, the mother's need for canakinumab therapy, and potential adverse effects of the drug
or an inadequately treated condition on the breast-fed infant.[41378] [61034]
Revision Date: 05/20/2020 10:20:53 AM
References
41378 – Ilaris (canakinumab) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016
Sep.
61034 – National Institutes of Health (NIH). Canakinumab monograph. LactMed: Drugs and Lactation
Database. Available at: https://toxnet.nlm.nih.gov. Accessed July 29, 2016.
Interactions
Level 1 (Severe)
Level 2 (Major)
Level 3 (Moderate)
Anakinra: (Major) Concomitant use of anakinra with other drugs that also block interleukin (IL)-1, such as
canakinumab, is not recommended; coadministration has not been studied and may result in additive
immunosuppression and increased risk of infection. [27940] [41378]
Bacillus Calmette-Guerin Vaccine, BCG: (Major) Do not administer live vaccines to a patient who is receiving
canakinumab; other vaccination schedules should be complete as recommended prior to initiating canakinumab
Rilonacept Tumor Necrosis Factor modifiers
Anakinra
Bacillus Calmette-Guerin Vaccine, BCG
Baricitinib
Encorafenib
Influenza Virus Vaccine
Intranasal Influenza Vaccine
Live Vaccines
Measles Virus; Mumps Virus; Rubella Virus;
Varicella Virus Vaccine, Live
Measles/Mumps/Rubella Vaccines, MMR
Rotavirus Vaccine
Rubella Virus Vaccine Live
Sarilumab
Smallpox and Monkeypox Vaccine, Live,
Nonreplicating
Smallpox Vaccine, Vaccinia Vaccine
Tocilizumab
Tofacitinib
Typhoid Vaccine
Upadacitinib
Varicella-Zoster Virus Vaccine, Live
Yellow Fever Vaccine, Live
Carbamazepine
Cyclosporine
Ethosuximide
Fosphenytoin
Phenytoin
Tacrolimus
Theophylline, Aminophylline
Warfarin
treatment. No data are available regarding the risk of secondary transmission of infection by live vaccines, and
the efficacy and safety of live vaccines have not been established in patients receiving canakinumab. The
immune response to vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune
response to new antigens. Limited data are available on the effectiveness of vaccination with inactivated
antigens in patients receiving canakinumab. Because interleukin-1 blockade may interfere with immune
response to infections, it is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive any recommended vaccination (including pneumococcal vaccine and inactivated
influenza vaccines). [41378] [43236]
Baricitinib: (Major) Concomitant use of baricitinib with biologic DMARDs, such as canakinumab, is not
recommended because of the possibility of additive immunosuppression and increased infection risk. [63229]
Carbamazepine: (Moderate) If canakinumab is initiated or discontinued in a patient taking carbamazepine,
monitor carbamazepine concentrations; carbamazepine dose adjustments may be needed. The formation of
CYP450 enzymes may be altered by increased concentrations of cytokines during chronic inflammation. Thus,
the formation of CYP450 enzymes could be normalized during canakinumab administration. In theory, clinically
relevant drug interactions may occur with CYP450 substrates that have a narrow therapeutic index such as
carbamazepine. [41378]
Cyclosporine: (Moderate) If canakinumab is initiated or discontinued in a patient taking cyclosporine, monitor
cyclosporine concentrations; cyclosporine dose adjustments may be needed. The formation of CYP450 enzymes
may be altered by increased concentrations of cytokines during chronic inflammation. Thus, the formation of
CYP450 enzymes could be normalized during canakinumab administration. In theory, clinically relevant drug
interactions may occur with CYP450 substrates that have a narrow therapeutic index such as cyclosporine. 
[41378]
Encorafenib: (Major) Avoid coadministration of encorafenib and canakinumab due to increased encorafenib
exposure. If concurrent use cannot be avoided, reduce the encorafenib dose to one-half of the dose used prior to
the addition of canakinumab. If canakinumab is discontinued, the original encorafenib dose may be resumed
after 3 to 5 elimination half-lives of canakinumab. Encorafenib is a CYP3A4 substrate; canakinumab is a
moderate CYP3A4 inhibitor. Coadministration of a moderate CYP3A4 inhibitor with a single 50 mg dose of
encorafenib (0.1 times the recommended dose) increased the encorafenib AUC and Cmax by 2-fold and 45%,
respectively. [41378] [63317]
Ethosuximide: (Moderate) If canakinumab is initiated or discontinued in a patient taking ethosuximide, monitor
ethosuximide concentrations; ethosuximide dose adjustments may be needed. The formation of CYP450
enzymes may be altered by increased concentrations of cytokines during chronic inflammation. Thus, the
formation of CYP450 enzymes could be normalized during canakinumab administration. In theory, clinically
relevant drug interactions may occur with CYP450 substrates that have a narrow therapeutic index such as
ethosuximide. [41378]
Fosphenytoin: (Moderate) If canakinumab is initiated or discontinued in a patient taking fosphenytoin, monitor
phenytoin concentrations; fosphenytoin dose adjustments may be needed. The formation of CYP450 enzymes
may be altered by increased concentrations of cytokines during chronic inflammation. Thus, the formation of
CYP450 enzymes could be normalized during canakinumab administration. In theory, clinically relevant drug
interactions may occur with CYP450 substrates that have a narrow therapeutic index such as fosphenytoin. 
[41378]
Influenza Virus Vaccine: (Major) Do not administer live vaccines to a patient who is receiving canakinumab;
other vaccination schedules should be complete as recommended prior to initiating canakinumab treatment. No
data are available regarding the risk of secondary transmission of infection by live vaccines, and the efficacy and
safety of live vaccines have not been established in patients receiving canakinumab. The immune response to
vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune response to new
antigens. Limited data are available on the effectiveness of vaccination with inactivated antigens in patients
receiving canakinumab. Because interleukin-1 blockade may interfere with immune response to infections, it is
recommended that prior to initiation of therapy with canakinumab, adult and pediatric patients receive any
recommended vaccination (including pneumococcal vaccine and inactivated influenza vaccines). [41378] [43236]
Intranasal Influenza Vaccine: (Major) Do not administer live vaccines to a patient who is receiving
canakinumab; other vaccination schedules should be complete as recommended prior to initiating canakinumab
treatment. No data are available regarding the risk of secondary transmission of infection by live vaccines, and
the efficacy and safety of live vaccines have not been established in patients receiving canakinumab. The
immune response to vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune
response to new antigens. Limited data are available on the effectiveness of vaccination with inactivated
antigens in patients receiving canakinumab. Because interleukin-1 blockade may interfere with immune
response to infections, it is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive any recommended vaccination (including pneumococcal vaccine and inactivated
influenza vaccines). [41378] [43236]
Live Vaccines: (Major) Do not administer live vaccines to a patient who is receiving canakinumab; other
vaccination schedules should be complete as recommended prior to initiating canakinumab treatment. No data
are available regarding the risk of secondary transmission of infection by live vaccines, and the efficacy and
safety of live vaccines have not been established in patients receiving canakinumab. The immune response to
vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune response to new
antigens. Limited data are available on the effectiveness of vaccination with inactivated antigens in patients
receiving canakinumab. Because interleukin-1 blockade may interfere with immune response to infections, it is
recommended that prior to initiation of therapy with canakinumab, adult and pediatric patients receive any
recommended vaccination (including pneumococcal vaccine and inactivated influenza vaccines). [41378] [43236]
Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live: (Major) Do not administer live
vaccines to a patient who is receiving canakinumab; other vaccination schedules should be complete as
recommended prior to initiating canakinumab treatment. No data are available regarding the risk of secondary
transmission of infection by live vaccines, and the efficacy and safety of live vaccines have not been established
in patients receiving canakinumab. The immune response to vaccines or toxoids may be decreased, as
canakinumab may interfere with normal immune response to new antigens. Limited data are available on the
effectiveness of vaccination with inactivated antigens in patients receiving canakinumab. Because interleukin-1
blockade may interfere with immune response to infections, it is recommended that prior to initiation of therapy
with canakinumab, adult and pediatric patients receive any recommended vaccination (including pneumococcal
vaccine and inactivated influenza vaccines). [41378] [43236]
Measles/Mumps/Rubella Vaccines, MMR: (Major) Do not administer live vaccines to a patient who is receiving
canakinumab; other vaccination schedules should be complete as recommended prior to initiating canakinumab
treatment. No data are available regarding the risk of secondary transmission of infection by live vaccines, and
the efficacy and safety of live vaccines have not been established in patients receiving canakinumab. The
immune response to vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune
response to new antigens. Limited data are available on the effectiveness of vaccination with inactivated
antigens in patients receiving canakinumab. Because interleukin-1 blockade may interfere with immune
response to infections, it is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive any recommended vaccination (including pneumococcal vaccine and inactivated
influenza vaccines). [41378] [43236]
Phenytoin: (Moderate) If canakinumab is initiated or discontinued in a patient taking phenytoin, monitor
phenytoin concentrations; phenytoin dose adjustments may be needed. The formation of CYP450 enzymes may
be altered by increased concentrations of cytokines during chronic inflammation. Thus, the formation of
CYP450 enzymes could be normalized during canakinumab administration. In theory, clinically relevant drug
interactions may occur with CYP450 substrates that have a narrow therapeutic index such as phenytoin. [41378]
Rilonacept: (Severe) The concomitant administration of canakinumab with other drugs that block interleukin
(IL)-1, such as rilonacept, has not been studied; however, based upon the potential for serious infection
associated with the use of both drugs, concomitant administration of canakinumab with rilonacept is not
recommended. [41378]
Rotavirus Vaccine: (Major) Do not administer live vaccines to a patient who is receiving canakinumab; other
vaccination schedules should be complete as recommended prior to initiating canakinumab treatment. No data
are available regarding the risk of secondary transmission of infection by live vaccines, and the efficacy and
safety of live vaccines have not been established in patients receiving canakinumab. The immune response to
vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune response to new
antigens. Limited data are available on the effectiveness of vaccination with inactivated antigens in patients
receiving canakinumab. Because interleukin-1 blockade may interfere with immune response to infections, it is
recommended that prior to initiation of therapy with canakinumab, adult and pediatric patients receive any
recommended vaccination (including pneumococcal vaccine and inactivated influenza vaccines). [41378] [43236]
Rubella Virus Vaccine Live: (Major) Do not administer live vaccines to a patient who is receiving canakinumab;
other vaccination schedules should be complete as recommended prior to initiating canakinumab treatment. No
data are available regarding the risk of secondary transmission of infection by live vaccines, and the efficacy and
safety of live vaccines have not been established in patients receiving canakinumab. The immune response to
vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune response to new
antigens. Limited data are available on the effectiveness of vaccination with inactivated antigens in patients
receiving canakinumab. Because interleukin-1 blockade may interfere with immune response to infections, it is
recommended that prior to initiation of therapy with canakinumab, adult and pediatric patients receive any
recommended vaccination (including pneumococcal vaccine and inactivated influenza vaccines). [41378] [43236]
Sarilumab: (Major) Avoid using sarilumab with other biological DMARDs including interleukin-1 receptor
antagonists such as canakinumab; coadministration has not been studied and may result in additive
immunosuppression and increased risk of infection. [61976]
Smallpox and Monkeypox Vaccine, Live, Nonreplicating: (Major) Do not administer live vaccines to a patient
who is receiving canakinumab; other vaccination schedules should be complete as recommended prior to
initiating canakinumab treatment. No data are available regarding the risk of secondary transmission of infection
by live vaccines, and the efficacy and safety of live vaccines have not been established in patients receiving
canakinumab. The immune response to vaccines or toxoids may be decreased, as canakinumab may interfere
with normal immune response to new antigens. Limited data are available on the effectiveness of vaccination
with inactivated antigens in patients receiving canakinumab. Because interleukin-1 blockade may interfere with
immune response to infections, it is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive any recommended vaccination (including pneumococcal vaccine and inactivated
influenza vaccines). [41378] [43236]
Smallpox Vaccine, Vaccinia Vaccine: (Major) Do not administer live vaccines to a patient who is receiving
canakinumab; other vaccination schedules should be complete as recommended prior to initiating canakinumab
treatment. No data are available regarding the risk of secondary transmission of infection by live vaccines, and
the efficacy and safety of live vaccines have not been established in patients receiving canakinumab. The
immune response to vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune
response to new antigens. Limited data are available on the effectiveness of vaccination with inactivated
antigens in patients receiving canakinumab. Because interleukin-1 blockade may interfere with immune
response to infections, it is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive any recommended vaccination (including pneumococcal vaccine and inactivated
influenza vaccines). [41378] [43236]
Tacrolimus: (Moderate) If canakinumab is initiated or discontinued in a patient taking tacrolimus, monitor
tacrolimus concentrations; tacrolimus dose adjustments may be needed. The formation of CYP450 enzymes may
be altered by increased concentrations of cytokines during chronic inflammation. Thus, the formation of
CYP450 enzymes could be normalized during canakinumab administration. In theory, clinically relevant drug
interactions may occur with CYP450 substrates that have a narrow therapeutic index such as tacrolimus. [41378]
Theophylline, Aminophylline: (Moderate) If canakinumab is initiated or discontinued in a patient taking
aminophylline, monitor theophylline concentrations; aminophylline dose adjustments may be needed. The
formation of CYP450 enzymes may be altered by increased concentrations of cytokines during chronic
inflammation. Thus, the formation of CYP450 enzymes could be normalized during canakinumab
administration. In theory, clinically relevant drug interactions may occur with CYP450 substrates that have a
narrow therapeutic index such as aminophylline. [41378] (Moderate) If canakinumab is initiated or discontinued
in a patient taking theophylline, monitor theophylline concentrations; theophylline dose adjustments may be
needed. The formation of CYP450 enzymes may be altered by increased concentrations of cytokines during
chronic inflammation. Thus, the formation of CYP450 enzymes could be normalized during canakinumab
administration. In theory, clinically relevant drug interactions may occur with CYP450 substrates that have a
narrow therapeutic index such as theophylline. [41378]
Tocilizumab: (Major) Avoid using tocilizumab with other biological DMARDs including interleukin-1 receptor
antagonists such as canakinumab; coadministration has not been studied and may result in additive
immunosuppression and increased risk of infection. [38283]
Tofacitinib: (Major) Concomitant use of tofacitinib with biologic DMARDs, such as canakinumab, is not
recommended because of the possibility of additive immunosuppression and increased infection risk. Tofacitinib
may be used as monotherapy or concomitantly with methotrexate or other nonbiologic DMARDs. [52315]
Tumor Necrosis Factor modifiers: (Severe) The concomitant administration of tumor necrosis factor (TNF)
modifiers with other drugs that block interleukin (IL)-1, such as canakinumab, has not been studied; however, an
increased incidence of serious infections and an increased risk of neutropenia have been associated with
administration of another IL-1 blocker in combination with TNF inhibitors. Based upon the potential for similar
interactions, concomitant administration of TNF inhibitors and canakinumab is not recommended. [41378]
Typhoid Vaccine: (Major) Do not administer live vaccines to a patient who is receiving canakinumab; other
vaccination schedules should be complete as recommended prior to initiating canakinumab treatment. No data
are available regarding the risk of secondary transmission of infection by live vaccines, and the efficacy and
safety of live vaccines have not been established in patients receiving canakinumab. The immune response to
vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune response to new
antigens. Limited data are available on the effectiveness of vaccination with inactivated antigens in patients
receiving canakinumab. Because interleukin-1 blockade may interfere with immune response to infections, it is
recommended that prior to initiation of therapy with canakinumab, adult and pediatric patients receive any
recommended vaccination (including pneumococcal vaccine and inactivated influenza vaccines). [41378] [43236]
Upadacitinib: (Major) Concomitant use of upadacitinib with biologic DMARDs, such as canakinumab, is not
recommended because of the possibility of increased immunosuppression and increased infection risk.
Upadacitinib may be used as monotherapy or concomitantly with methotrexate or other nonbiologic DMARDs. 
[64572]
Varicella-Zoster Virus Vaccine, Live: (Major) Do not administer live vaccines to a patient who is receiving
canakinumab; other vaccination schedules should be complete as recommended prior to initiating canakinumab
treatment. No data are available regarding the risk of secondary transmission of infection by live vaccines, and
the efficacy and safety of live vaccines have not been established in patients receiving canakinumab. The
immune response to vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune
response to new antigens. Limited data are available on the effectiveness of vaccination with inactivated
antigens in patients receiving canakinumab. Because interleukin-1 blockade may interfere with immune
response to infections, it is recommended that prior to initiation of therapy with canakinumab, adult and
pediatric patients receive any recommended vaccination (including pneumococcal vaccine and inactivated
influenza vaccines). [41378] [43236]
Warfarin: (Moderate) If canakinumab is initiated or discontinued in a patient taking warfarin, monitor the INR;
warfarin dose adjustments may be needed. The formation of CYP450 enzymes may be altered by increased
concentrations of cytokines during chronic inflammation. Thus, the formation of CYP450 enzymes could be
normalized during canakinumab administration. In theory, clinically relevant drug interactions may occur with
CYP450 substrates that have a narrow therapeutic index such as warfarin. [28549] [41378]
Yellow Fever Vaccine, Live: (Major) Do not administer live vaccines to a patient who is receiving canakinumab;
other vaccination schedules should be complete as recommended prior to initiating canakinumab treatment. No
data are available regarding the risk of secondary transmission of infection by live vaccines, and the efficacy and
safety of live vaccines have not been established in patients receiving canakinumab. The immune response to
vaccines or toxoids may be decreased, as canakinumab may interfere with normal immune response to new
antigens. Limited data are available on the effectiveness of vaccination with inactivated antigens in patients
receiving canakinumab. Because interleukin-1 blockade may interfere with immune response to infections, it is
recommended that prior to initiation of therapy with canakinumab, adult and pediatric patients receive any
recommended vaccination (including pneumococcal vaccine and inactivated influenza vaccines). [41378] [43236]
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